journal article·2025-07-04

Self-Assembled Drug Nanocomplexes Reverses Tumor Thermoresistance and Depletes GSH to Optimize Mild Photothermal Therapy for Osteosarcoma

Chi Zhang, Tao Ding, Tangbing Xu, Jun Chang, Yunfeng Wu, Yong Liu, Fei Huang, Xiaoyan He, Yong Hu

ACS Applied Nano Materials· Volume 8· Issue 26
Publisher page

Abstract

Osteosarcoma, a highly aggressive malignant bone tumor, presents significant treatment challenges. Photothermal therapy (PTT) is a promising therapeutic approach for OS; however, its efficacy is limited by dual resistance mechanisms: overexpression of heat shock protein 70 (HSP70) in tumor cells, which activates thermal defense pathways, and glutathione-mediated scavenging of photothermal-derived reactive oxygen species (ROS). To address these limitations, we developed a multifunctional nanodrug (CAI) via noncovalent assembly of Cu 2+, apoptozole, and indocyanine green (ICG). In this system, apoptozole suppresses HSP70 to attenuate thermal resistance, while Cu 2+ depletes GSH to amplify oxidative damage. Apoptozole and Cu 2+ synergistically enhance the photothermal tumor ablation effect of ICG under laser irradiation. The results demonstrate preferential tumor accumulation of CAI via the enhanced permeation and retention (EPR) effect. Following cellular internalization, the acidic tumor microenvironment triggers CAI dissociation, releasing Cu 2+ and apoptozole to synergistically sensitize OS cells to concurrent thermal and oxidative damage. This dual-action mechanism enhances mild PTT efficacy against OS while maintaining favorable biocompatibility. Transcriptomic profiling further revealed CAI-mediated modulation of immune response pathways, inflammatory chemotaxis, and ferroptosis-related signaling, suggesting potential for multimodal OS therapy. Our study proposes a rationally designed strategy to circumvent HSP70 and glutathione-mediated resistance in PTT and broadens the therapeutic arsenal for OS.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Extracellular vesicles in disease · Nanoparticle-Based Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Orthopaedics, The First Affiliated Hospital of Anhui Medical University, No. 218, Jixi Road, Shushan District, Hefei City 230000, China

Department of Orthopaedics, Anhui Public Health Clinical Center, No. 100, Huaihai Road, Xinzhan District, Hefei City 230000, China

Department of Orthopaedics, The Second Affiliated Hospital of Anhui Medical University, No. 678, Furong Road, Shushan District, Hefei City 230000, China

School of Life Sciences Anhui Medical University, Yuhuangshan Road, Yaohai District, Hefei City 230000, China

Funding

Anhui Medical University · Natural Science Foundation of Anhui Province · Anhui Provincial Science Research Project Fund for Colleges and Universities · Anhui Institute of translational medicine · Natural science fund for colleges and universities in Anhui Province

References (45)

Show source-provided references
1. 10.3389/fimmu.2023.129076210.3389/fimmu.2023.1290762 ↗
2. 10.1245/s10434-009-0825-610.1245/s10434-009-0825-6 ↗
3. 10.1038/s41572-022-00409-y10.1038/s41572-022-00409-y ↗
4. 10.1200/JCO.2014.59.489510.1200/JCO.2014.59.4895 ↗
5. 10.1038/s41571-021-00519-810.1038/s41571-021-00519-8 ↗
6. 10.1016/j.colsurfb.2022.11250710.1016/j.colsurfb.2022.112507 ↗
7. 10.1002/adma.20170358810.1002/adma.201703588 ↗
8. 10.1016/j.jcis.2025.13768810.1016/j.jcis.2025.137688 ↗
9. 10.1186/s12951-023-01961-910.1186/s12951-023-01961-9 ↗
10. 10.1186/s12951-024-02419-210.1186/s12951-024-02419-2 ↗
11. 10.1039/D2BM01900K10.1039/D2BM01900K ↗
12. 10.1039/D0TB00248H10.1039/D0TB00248H ↗
13. 10.1002/adma.20230031310.1002/adma.202300313 ↗
14. 10.3390/ijms2508413910.3390/ijms25084139 ↗
15. 10.1186/s12951-023-02111-x10.1186/s12951-023-02111-x ↗
16. 10.1039/D2BM01833K10.1039/D2BM01833K ↗
17. 10.1186/s12951-021-01080-310.1186/s12951-021-01080-3 ↗
18. 10.3390/pharmaceutics1411227910.3390/pharmaceutics14112279 ↗
19. 10.1111/cpr.1310210.1111/cpr.13102 ↗
20. 10.1038/s41467-019-11269-810.1038/s41467-019-11269-8 ↗
21. 10.1016/j.actbio.2024.07.03210.1016/j.actbio.2024.07.032 ↗
22. 10.1186/s12951-023-01818-110.1186/s12951-023-01818-1 ↗
23. 10.1002/adhm.20230092910.1002/adhm.202300929 ↗
24. 10.1021/cr500419810.1021/cr5004198 ↗
25. 10.1021/acsnano.3c0949910.1021/acsnano.3c09499 ↗
26. 10.3390/biom1010142910.3390/biom10101429 ↗
27. 10.1021/acs.langmuir.2c0348910.1021/acs.langmuir.2c03489 ↗
28. 10.1007/s00018-004-4464-610.1007/s00018-004-4464-6 ↗
29. 10.3390/cells903058710.3390/cells9030587 ↗
30. 10.1016/j.chembiol.2018.06.01010.1016/j.chembiol.2018.06.010 ↗
31. 10.1002/iub.215710.1002/iub.2157 ↗
32. 10.1016/j.canlet.2016.01.05610.1016/j.canlet.2016.01.056 ↗
33. 10.1016/j.jcis.2018.12.07210.1016/j.jcis.2018.12.072 ↗
34. 10.1016/j.jcis.2022.06.11710.1016/j.jcis.2022.06.117 ↗
35. 10.1002/smll.20210386810.1002/smll.202103868 ↗
36. 10.1002/smll.20230114810.1002/smll.202301148 ↗
37. 10.1016/j.jcis.2021.04.13110.1016/j.jcis.2021.04.131 ↗
38. 10.3390/molecules2823775010.3390/molecules28237750 ↗
39. 10.1021/acsabm.3c0082610.1021/acsabm.3c00826 ↗
40. 10.3389/fimmu.2023.112525310.3389/fimmu.2023.1125253 ↗
41. 10.1002/smll.20220693310.1002/smll.202206933 ↗
42. 10.1007/978-1-60761-756-3_1810.1007/978-1-60761-756-3_18 ↗
43. 10.1038/ncomms1043710.1038/ncomms10437 ↗
44. 10.1016/j.ajps.2021.10.00110.1016/j.ajps.2021.10.001 ↗
45. 10.1002/adfm.20240180610.1002/adfm.202401806 ↗